Glenmark Pharmaceuticals Ltd (NSE:GLENMARK)
₹ 1194.15 -15.7 (-1.3%) Market Cap: 336.71 Bil Enterprise Value: 330.69 Bil PE Ratio: 0 PB Ratio: 4.29 GF Score: 83/100

Q1 2022 Glenmark Pharmaceuticals Ltd Earnings Call Transcript

Aug 16, 2021 / 04:00AM GMT
Release Date Price: ₹569.35 (+1.08%)
Operator

Ladies and gentlemen, good day, and welcome to the Q1 FY '22 Earnings Conference Call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Mr. Ravi Agarwal. Thank you, and over to you, sir.

Ravi Agrawal
Glenmark Pharmaceuticals Limited - IR Officer

Yes. Thank you, moderator. Good morning, everyone, and a warm welcome to the Q1 FY '22 Results Conference Call of Glenmark Pharmaceuticals Limited. Before we start the call, a review of operations of the company. For the first quarter of FY '21/'22, Glenmark's consolidated revenue from operations was at INR 29,649 million, as against INR 23,448 million, recording an increase of 26.4% year-on-year.

On to the businesses. First, the India business. Sales from the formulations business in India for the first quarter FY '21/'22 was at INR 12,250 million, recording a growth of 57.1% year-on-year. Q1 FY '22 was a landmark quarter for the India business with both the COVID and non-COVID portfolios of the company

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot